Eurasian Hematology-Oncology Group

http://www.ehog.net/

 

XIth Eurasian Hematology-Oncology Congress - EHOC 2020
M

MDS Essentials: How Common Are Comorbidities? Should Risk Score Determine the Treatment Goal? What if the Patients Are Not Eligible for HSCT?

By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Mustafa Çetiner
By XIth Eurasian Hematology-Oncology Congress - EHOC 2020 FEATURING Mustafa Çetiner
70 views
January 18, 2021
0 Comments
Login to view comments. Click here to Login

Featured Video

13:04
Winship Cancer Institute - Emory University

Treatment-Related Quality of Life in MF

Feat. A. Hunter

Featured Video

06:51
Insights from 2023 ASH Annual Meeting

ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…

Feat. D. Tremblay
MDS and MPN
21:56
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Leukemic Transformations of MPNs: What Mutations Are Associated With…

Feat. T. Mughal
25:23
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Essentials: How Common Are Comorbidities? Should Risk Score Dete…

Feat. M. Çetiner
09:57
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

LR-MDS: Are ESAs Effective in the Treatment of Anemia? Is PLT Transf…

Feat. M. Mittelman
10:25
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

HR-MDS: Are HMAs the Best Option? Should We Consider Changing the Pa…

Feat. M. Mittelman
22:45
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

Novel Approaches for PV: Can We Achieve CHR and Improve Disease Burd…

Feat. M. Ellis
12:47
XIth Eurasian Hematology-Oncology Congress - EHOC 2020

MDS Updates: Can We Achieve Long-Term Transfusion Independence With …

Feat. G. Garcia-Manero